臨床泌尿器科77巻3号

2023年03月発行

特集 最新版!　筋層浸潤性膀胱癌の診断と治療―アンメットニーズはどこまで埋まったか

〈治療〉

転移性膀胱癌に対する三次薬物治療

著者： 北野剛士¹ 小島崇宏¹

所属機関： ¹愛知県がんセンター泌尿器科部

ページ範囲：P.266 - P.272

文献概要

▶ポイント

・転移性膀胱癌に対する三次治療として，2021年に抗体薬物複合体（ADC）製剤であるenfortumab vedotin（EV）が国内承認された．

・EVのほかにADC製剤として，HER2-ADCやTROP2-ADCといったさまざまな薬剤開発が盛んに行われている．

・がんゲノム医療の普及によりFGFR阻害薬などの治療選択が増えれば，三次治療以降の治療体系も今後大きく変わる可能性がある．

参考文献

1） Nadal R, et al : Management of Metastatic Bladder Cancer. Cancer Treat Rev 76 : 10-21, 2019

2） Sternberg CN, et al : Preliminary Results of M-VAC （Methotrexate, Vinblastine, Doxoruvicin and Cisplatin） for Transitional Cell Carcinoma of the Urothlium. J Urol 133 : 403-407, 1985

3） Von der Maase H, et al : Gemcitabine and Cisplatin versus Methotrexate, Vinblastin, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer : Results of a Large, Ramdomized, Multinational, Multicenter, Phase III Study. J Clin Oncol 18 : 3068-3077, 2000

4） Joly F, et al : Do patients with Advanced Urothelial Carcinoma Benefit from Weekly Paclitaxel Chemotherapy? A GETUG Phase II Study. Clin Genitourin Cancer 7 : E28-E33, 2009

5） McCaffrey JA, et al : Phase II Trial of Docetaxel in Patients with Advanced or Metastatic Transitional-Cell Carcinoma. J Clin Oncol 15 : 1853-1857, 1997

6） Bellmunt J, et al : Phase III Trial of Vinflunine plus Best Supportive Care Compared with Best Supportive Care Alone After a Platinum-Containing Regimen in Patients with Advanced Transitional Cell Carcinoma of the Urothelial Tract. J Clin Oncol 27 : 4454-4461, 2009

7） Rosenberg JE, et al : Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy. J Clin Oncol 37 : 2592-2600, 2019

8） Powles T, et al : Enfortumab Vedotin in Previ- Ously Treated Advanced Urothelial Carcinoma. N Engl J Med 384 : 1125-1135, 2021

9） Loriot Y, et al : Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. N Engl J Med 381 : 338-348, 2019

10） Iyer G, et al : Prevalence and Co-Occurrence of Actionable Genomic Alterations in High-Grade Bladder Cancer. J Clin Oncol 31 : 3133-3140, 2013

11） Albarrán V, et al : Her-2 Targeted Therapy in Advanced Urothelial Cancer : From Monoclonal Antibodies to Antibody-Drug Conjugates. Int J Mol Sci 23 : 12659, 2022

12） Banerji U, et al : Trastuzumab Duocarmazine in Locally Advanced and Metastatic Solid Tumours and HER2-Expressing Breast Cancer : A Phase 1 Dose-Escalation and Dose-Expansion Study. Lancet Oncol 20 : 1124-1135, 2019

13） Shi F, et al : Disitamab Vedotin. A novel Antibody-Drug Conjugates for Cancer Therapy. Drug Deliv 29 : 1335-1344, 2022

14） Sheng X, et al : Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma. Clin Cancer Res 27 : 43-51, 2021

15） Tamura K, et al : Trastuzumab Deruxtecan （DS-8201a） in Patients with Advanced HER2-Positive Breast Cancer Previously Treated with Trastuzumab Emtansine : A Dose-Expansion, Phase 1 Study. Lancet Oncol 20 : 816-826, 2019

16） Goldenberg DM, et al : Trop-2 Is a Novel Target for Solid Cancer Therapy with Sacituzumab Govitecan （IMMU-132）, an Antibody-Drug Conjugate （ADC）. Oncotarget 6 : 22496-22512, 2015

17） Tagawa ST, et al : TROPHY-U-01 : A Phase II Open-Label Study of Sacituzumab Govitecan in Patients with Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors. J Clin Oncol 39 : 2474-2485, 2021

18） Rosenberg J, et al : EV-101 : A Phase I Study of Single-Agent Enfortumab Vedotin in Patients with Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma. J Clin Oncol 38 : 1041-1049, 2020

19） Galsky MD, et al : Primary Analysis from DS8201-A-U105 : A Phase 1b, Two-Part, Open-Label Study of Trastuzumab Deruxtecan （T-DXd） with Nivolumab （nivo） in Patients （pts） with HER2-Expressing Urothelial Carcinoma （UC）. J Clin Oncol 40 : 438, 2022

20） Iwata TN, et al : A HER2- Targeting Antibody-Drug Conjugate, Trastuzumab Deruxtecan （DS-8201a）, Enhances Antitumor Immunity in a Mouse Model. Mol Cancer Ther 17 : 1494-1503, 2018

21） Rosenberg JE, et al : Study EV-103 : Preliminary Durability Results of Enfortumab Vedotin plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma. J Clin Oncol 38 : 441, 2020

22） Cancer Genome Atlas Research Network : Comprehensive Molecular Characterization of Urothelial Bladder Carcinoma. Nature 507 : 315-322, 2014

23） Kim JW, et al : Sapanisertib, a Dual mTORC1/2 Inhibitor, for TSC1- or TSC2-Mutated Metastatic Urothelial Carcinoma （mUC）. J Clin Oncol 39 : 431, 2021

Genomic Alterations and Their Association with Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity. JCO Precis Oncol 4 : 442-465, 2020

25） Yang H, et al : Olaparib Is Effective for Recurrent Urothelial Carcinoma with BRCA2 Pathogenic Germline Mutation : First Report on Olaparib Response in Recurrent UC. Ther Adv Med Oncol 12 : 1758835920970845, 2020